Kimberly Manhard
2022
In 2022, Kimberly Manhard earned a total compensation of $1.4M as Executive Vice President, Drug Development at Heron Therapeutics, a 22% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $204,688 |
|---|---|
| Option Awards | $235,482 |
| Salary | $545,834 |
| Stock Awards | $441,456 |
| Other | $19,647 |
| Total | $1,447,107 |
Manhard received $545.8K in salary, accounting for 38% of the total pay in 2022.
Manhard also received $204.7K in non-equity incentive plan, $235.5K in option awards, $441.5K in stock awards and $19.6K in other compensation.
Rankings
In 2022, Kimberly Manhard's compensation ranked 2,268th out of 5,534 executives tracked by ExecPay. In other words, Manhard earned more than 59.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,268 out of 5,534 | 59th |
Division Manufacturing | 1,227 out of 3,000 | 59th |
Major group Chemicals And Allied Products | 544 out of 1,350 | 60th |
Industry group Drugs | 499 out of 1,253 | 60th |
Industry Pharmaceutical Preparations | 361 out of 907 | 60th |
Source: SEC filing on May 1, 2023.
Manhard's colleagues
We found two more compensation records of executives who worked with Kimberly Manhard at Heron Therapeutics in 2022.
News
Heron Therapeutics Executive Vice President, Drug Development Kimberly Manhard's 2022 pay falls 22% to $1.4M
May 1, 2023
Heron Therapeutics CEO Barry Quart's 2021 pay rises 2% to $5.4M
April 25, 2022
Heron Therapeutics CEO Barry Quart's 2020 pay slips 9% to $5.3M
April 22, 2021
Heron Therapeutics CEO Barry Quart's 2019 pay slips 2% to $5.9M
April 23, 2020